Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system

Annals of Thoracic Surgery

Volumn 68, Issue 5, 1999, Pages 1756-1760

  Lambright, Eric S ^a   Caparrelli, David J ^a   Abbas, Abbas E ^a   Toyoizumi, Takane ^a   Coukos, George ^a   Molnar Kimber, Katherine L ^a   Kaiser, Larry R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0032751178     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00852-8     Document Type: Article

References (29)

1. Smythe W.R., Hwang H.C., Amin K.M., et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann Surg. 222:1995;78-86.
2. Roth J.A., Cristiano R.J. Gene therapy for cancer what have we done and where are we going? J Natl Cancer Inst. 89:1997;21-39.
3. Sterman D.H., Treat J., Litzky L.A., et al. Adenovirus mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy results of a phase I trial in malignant mesothelioma . Hum Gene Ther. 9:1998;1083-1092.
4. Molnar-Kimber K.L., Sterman D.H., Chang M.Y., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther. 9:1998;2121-2133.
5. Elshami A.A., Kucharczuk J.C., Sterman D.H., et al. The role on immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg. 222:1995;298-310.
6. Kozarsky K.F., McKinley D.R., Austin L.L., Raper S.E., Stratford-Perricaudett L.D., Wilson J.M. In vivo correction of low-density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem. 269:1994;13695-13702.
7. Michou A.I., Santoro L., Christ M., Julliard V., Pavirani A., Mehtali M. Adenovirus-mediated gene transfer influence of transgene, mouse strain and type of immune response on persistence of transgene expression . Gene Ther. 4:1997;473-482.
8. Yang Y., Li Q., Ertl H.C.J., Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 69:1995;2004-2015.
9. Kucharczuk J.C., Raper S., Elshami A.A., et al. Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Hum Gene Ther. 7:1996;2225-2233.
10. Russell S.J. Replicating vectors for gene therapy of cancer risks, limitations, and prospects . Eur J Cancer. 30A:1994;1165-1171.
11. Chou J., Kern E., Whitley R., Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma I34.5, a gene nonessential for growth in culture. Science. 250:1990;1262-1266.
12. MacLean A.R., ul-Fareed M., Robertson L., Harland J., Brown S.M. Herpes simplex virus type 1 deletion variant 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and "a" sequence. J Gen Virol. 72:1991;631-639.
13. Valyi-Nagy T., Fareed M.U., O'Keefe J.S., et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol. 75:1994;2059-2063.
14. Randazzo B.P., Kucharczuk J.C., Litzky L.A., et al. Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication restricted in human skin xenografts in vivo. Virology. 223:1996;392-396.
15. Brown S.M., MacLean A.R., Aitken J.D., Harland J. ICP34.5 influences herpes simplex virus type I maturation and egress from infected cells in vitro. J Gen Virol. 75:1994;3679-3686.
16. Kucharczuk J.C., Randazzo B., Chang M.Y., et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 57:1997;466-471.
17. Randazzo B.P., Kesari S., Geaser R.M., et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology. 211:1995;94-101.
18. McKie E.A., MacLean A.R., Lewis A.D., et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy. Br J Cancer. 74:1996;745-752.
19. Coukos G., Makrigiannakis A., Kang E.H., et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 5:1999;1523-1537.
20. Coukos G., Rubin S.R., Molnar-Kimber K.L. Application of recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther Mol Bio. 3:1999;79-89.
21. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1:1995;938-943.
22. Chambers R., Gillespie G.Y., Soroceanu L., et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc Natl Acad Sci USA. 92:1995;1411-1415.
23. Toda M., Rabkin S.D., Martuza R.L. Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex virus 1. Hum Gene Ther. 9:1998;2173-2185.
24. Sugiura K., Strock C.C. Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors. Cancer Res. 15:1955;38-51.
25. Ohe Y., Podack E.R., Olsen K.J., et al. Combination effect of vaccination with IL-2 and IL-4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer. 53:1993;432-437.
26. Porgador A., Tzehoval E., Katz A., et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:1992;3679-3686.
27. Redmond H.P., Schuchter L., Bartlett D., et al. Anti-neoplastic effects of interleukin-4. J Surg Res. 52:1992;406-411.
28. Andreansky S., He B., van Cott J., et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:1998;121-130.
29. Toda M., Martuza R.L., Kojima H., Rabkin S.D. In situ cancer vaccination an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity . J Immunol. 160:1998;4457-4464.